A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)

Summary

PROSPER trial is a trial to assess the efficacy of FNP-223 in slowing disease progression in participants with PSP as measured by the PSP Rating Scale (PSPRS) over 52 weeks and to assess the safety and tolerability of FNP-223 for 52 weeks in participants with PSP.

Timeline

Start

2024-07-23

Primary completion

2026-11

Completion

2026-11

Publications

• Pokorny R, Ryan JM, Abd-Elaziz K, van den Berg F, Rabiner E, Searle GE, Schneider M, Wiessner C, Stallaert JF, Permanne B, Quattropani A, Beher D. Safety, Tolerability, Pharmacokinetics, and Brain Target Occupancy of the OGA Inhibitor ASN90 in Healthy Participants. Mov Disord. 2026 Feb;41(2):436-444. doi: 10.1002/mds.70104. Epub 2025 Nov 15.

Drugs

Indications